- Report
- November 2022
Peru
From €1651EUR$1,850USD£1,456GBP
- Report
- November 2022
Paraguay
From €1651EUR$1,850USD£1,456GBP
- Report
- November 2022
Panama
From €1651EUR$1,850USD£1,456GBP
- Report
- November 2022
Pakistan
From €1651EUR$1,850USD£1,456GBP
- Report
- January 2022
China
From €2186EUR$2,450USD£1,928GBP
From €2186EUR$2,450USD£1,928GBP
- Report
- March 2024
- 132 Pages
Global
From €848EUR$950USD£747GBP
The NAT Screening market within the context of In Vitro Diagnostics is a segment of the healthcare industry that focuses on the development and commercialization of tests that detect the presence of infectious agents in a sample. These tests are used to diagnose and monitor the spread of infectious diseases, such as HIV, hepatitis, and other viruses. NAT Screening tests are used in a variety of settings, including clinical laboratories, hospitals, and public health departments.
NAT Screening tests are typically performed using a variety of technologies, such as polymerase chain reaction (PCR), nucleic acid hybridization, and enzyme-linked immunosorbent assays (ELISA). These tests are used to detect the presence of specific genetic material in a sample, which can be used to identify the presence of a particular infectious agent.
Some companies in the NAT Screening market include Abbott Laboratories, Becton Dickinson, Cepheid, Hologic, and Roche Diagnostics. Show Less Read more